Darzalex

J&J's Darzalex Proves Effective in Yet Another Multiple Myeloma Indication
J&J's Darzalex Proves Effective in Yet Another Multiple Myeloma Indication
BioSpace
JNJ
Genmab
clinical trials
Darzalex
Multiple Myeloma
Flag link:
J&J’s next-gen Darzalex sparks drug delivery royalties battle
J&J’s next-gen Darzalex sparks drug delivery royalties battle
Fierce Pharma
JNJ
Darzalex
Genmab
Halozyme
Flag link:
Genmab and Janssen Head to Arbitration Table Over Darzalex Royalties
Genmab and Janssen Head to Arbitration Table Over Darzalex Royalties
BioSpace
Genmab
JNJ
Janssen
Darzalex
arbitration
Multiple Myeloma
Flag link:
J&J adds yet another multiple myeloma regimen to the Darzalex label as Sanofi rival jumps in
J&J adds yet another multiple myeloma regimen to the Darzalex label as Sanofi rival jumps in
Endpoints
JNJ
Darzalex
FDA
Multiple Myeloma
Flag link:
With Sanofi entering the multiple myeloma market, J&J flashes data on new rare disease
With Sanofi entering the multiple myeloma market, J&J flashes data on new rare disease
Endpoints
EHA
JNJ
clinical trials
Darzalex
AL amyloidosis
Flag link:
EHA: Johnson & Johnson's Darzalex branches out beyond myeloma with AL amyloidosis win
EHA: Johnson & Johnson's Darzalex branches out beyond myeloma with AL amyloidosis win
Fierce Pharma
light chain amyloidosis
JNJ
Darzalex
EHA
Flag link:
J&J defends Darzalex with FDA approval for faster dosing
J&J defends Darzalex with FDA approval for faster dosing
Pharmaforum
JNJ
FDA
Darzalex
dosing
Multiple Myeloma
Flag link:
Johnson & Johnson Submits FDA Application for Multiple Myeloma Drug
Johnson & Johnson Submits FDA Application for Multiple Myeloma Drug
Motley Fool
JNJ
Janssen
Darzalex
daratumumab
Multiple Myeloma
Flag link:
ASH: J&J's Darzalex cuts death risk by 40% in new myeloma patients
ASH: J&J's Darzalex cuts death risk by 40% in new myeloma patients
Fierce Pharma
JNJ
Darzalex
Multiple Myeloma
ASH2019
Flag link:
J&J's Darzalex makes FDA history with another myeloma nod in new patients
J&J's Darzalex makes FDA history with another myeloma nod in new patients
Fierce Pharma
JNJ
Darzalex
FDA
Multiple Myeloma
Flag link:
Amgen's Kyprolis, J&J's Darzalex team up on myeloma survival win
Amgen's Kyprolis, J&J's Darzalex team up on myeloma survival win
Fierce Pharma
Amgen
Kyprolis
JNJ
Darzalex
Multiple Myeloma
Flag link:
J&J warns generics will bite its pharma unit in the second half
J&J warns generics will bite its pharma unit in the second half
Pharmaforum
JNJ
generics
biosimilars
Darzalex
Zytiga
Flag link:
FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex
FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex
Fierce Biotech
Sanofi
FDA
Darzalex
relapsed or refractory multiple myeloma
isatuximab
Flag link:
FDA quickly approves J&J’s Darzalex in multiple myeloma
FDA quickly approves J&J’s Darzalex in multiple myeloma
Pharmaforum
JNJ
Janssen
FDA
Darzalex
Multiple Myeloma
Flag link:
J&J bags $150M option on Genmab's Darzalex successor
J&J bags $150M option on Genmab's Darzalex successor
Fierce Biotech
Genmab
JNJ
Darzalex
Multiple Myeloma
drug development
Flag link:
ASCO: J&J eyes Darzalex convenience, safety boost with subcutaneous win
ASCO: J&J eyes Darzalex convenience, safety boost with subcutaneous win
Fierce Pharma
JNJ
Darzalex
ASCO 2019
Flag link:
J&J Seeks Approval for Darzalex in Expanded Patient Group
J&J Seeks Approval for Darzalex in Expanded Patient Group
Yahoo/Zacks.com
JNJ
Darzalex
Multiple Myeloma
FDA
Flag link:
Genmab's blockbuster Darzalex surpasses $2B in sales
Genmab's blockbuster Darzalex surpasses $2B in sales
BioCentury
Genmab
Multiple Myeloma
Darzalex
Flag link:
ASH: J&J's fast-growing Darzalex lines up for second front-line myeloma OK
ASH: J&J's fast-growing Darzalex lines up for second front-line myeloma OK
Fierce Pharma
JNJ
Darzalex
Multiple Myeloma
ASH 2018
Flag link:
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial
BioSpace
JNJ
Janssen
Genmab
Darzalex
clinical trials
Multiple Myeloma
Flag link:

Pages